EP0699197B1 - 4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen-4-on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie - Google Patents
4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen-4-on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie Download PDFInfo
- Publication number
- EP0699197B1 EP0699197B1 EP95913143A EP95913143A EP0699197B1 EP 0699197 B1 EP0699197 B1 EP 0699197B1 EP 95913143 A EP95913143 A EP 95913143A EP 95913143 A EP95913143 A EP 95913143A EP 0699197 B1 EP0699197 B1 EP 0699197B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- och
- chromen
- fluorobenzoyl
- piper
- propoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 COc(cc1)cc(OC(*)=C2*)c1C2=O Chemical compound COc(cc1)cc(OC(*)=C2*)c1C2=O 0.000 description 3
- ARTIZDJMTIAXRE-UHFFFAOYSA-N CC(C(C=O)C=C1)C=C1F Chemical compound CC(C(C=O)C=C1)C=C1F ARTIZDJMTIAXRE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Definitions
- the present invention relates to new chromene compounds having the general formula (I): wherein R 1 and R 2 are hydrogen, alkyl having from 1 to 4 carbon atoms, halogen, trifluoromethyl, phenyl, or hydroxymethyl, as well as their pharmaceutically acceptable addtion salts.
- hydrochloride is preferred.
- Acetonitrile is appropriate as a nonpolar solvent, and as a base it is useful to employ an alkali metal carbonate or hydrogen carbonate.
- Potassium iodide can be used as a catalyst.
- the reaction occurs under heating, preferably at the boiling temperature of the mixture.
- Intermediate (II) can be purchased from commercial source. This reaction can be illustrated according to Scheme 1.
- the intermediates of the general formula (III) wherein X is chlorine, bromine or iodine and R 1 and R 2 are hydrogen, alkyl having from 1 to 4 carbon atoms, halogen, trifluoromethyl, phenyl, may be prepared, although not in a limitative manner, a) by alkylation of the corresponding 7-hydroxy-chromen-4-ones of general formula (IV) wherein R 1 and R 2 are as defined in (I) with 1-bromo-3-halopropane of general formula (V) wherein X is as defined in (III), or b) by cyclization from the corresponding 4-(3-halopropoxy)-2-hydroxyacetophenones of general formula (VI) wherein X is as defined in the preceding structure, all of this according to Scheme 2.
- [Y] is a halogenating agent which is able to introduce a chlorine, bromine or iodine atom, such as tert -butyl hypochlorite, chlorine, bromine or iodine.
- a chlorine, bromine or iodine atom such as tert -butyl hypochlorite, chlorine, bromine or iodine.
- the intermediates of the general formula (III) wherein X is chlorine, bromine or iodine, R 1 is hydrogen and R 2 is hydroxymethyl may be prepared through two steps from the 4'-(halopropoxy)-2'-hydroxy-acetophenones of general formula (VI) by alkylation in dimethylformamide with phosphoryl chloride followed by addition on ice and subsequent reduction of the so-formed 7-(3-halopropoxy)-3-formyl-chromen-4-ones of general formula (IX) wherein X is as defined in the preceding structures with sodium borohydride according to conventional procedures of organic chemistry as shown in Scheme 2'.
- the raw material required for performing the reactions shown in these schemes may be obtained either from commercial sources or according to conventional procedures of organic chemistry.
- EP Patent No. 546389 discloses substituted piperidyl-methyl chromanes as dopamine and serotonin receptor inhibitors which are potentially useful for treating CNS diseases, such as anxiety, depression, psychosis, Alzheimer's disease, etc.
- EP Patent No. 441506 discloses 3-piperidino-4-hydroxy-chromanes that can be used in the treatment of CNS diseases, such as stroke, Alzheimer's disease, Parkinson's disease and Huntington's disease.
- PCT Patent application No. 9012795 discloses substituted chromanes that are potentially useful for treating CNS diseases, such as aggressive behaviour, delirium and confusion, and impotence.
- 8702359 discloses aminoalcohols from the family of dihydrobenzothiophene and thiochromane having antihypertensive, antithrombotic, hypolipidemic, spasmolytic, calcium antagonist and neuroleptic actions.
- US Patent No. 4678787 discloses 4H-1-benzopyran-4-ones and their analogs containing sulfur, which are potentially useful to treat psychosis and schizophrenia.
- US Patent No. 4617314 discloses dihydrobenzofuranyl- and benzopyranyl-carboxamides having antidopamine, antiemetic and methamphetamine potentiating actions.
- EP-A-0 190 015 and J. Med. Chem. (1991), 34(1), P. 248-256 disclose 4H-1-benzopyran-4-ones and their sulfur containing analogues which are said to be efficient for the treatment of psychosis including schizophrenia.
- WO-A-91 18597 and J. Med. Chem. (1992), 35(9), p. 1526-1535 disclose compounds of the formula wherein A1, A2, A3, X, Y, and Z have specified meanings. The compounds are said to be useful to inhibit ⁇ binding site-induced activity.
- EP-A-0 064 255 discloses compounds which are 4-benzamidopiperidin-1-ylalkoxychromen-4-one derivatives which exhibit anti-allergenic, anti-anaphylactic activities.
- WO-A-90 06921 discloses inter alia compounds which are arylpiperidin-1-yl-1-alkoxychromen-4-one derivatives which show anti-thrombotic, anti-atherosclerotic activities.
- EP-A-0 558 245 discloses compounds which are 4-arylpiperidin-1-yl-alkoxychromen-4-one derivatives which show hypertensive activities.
- the compounds of formula (I) are different from the compounds disclosed in the aforesaid patents and prove not to be obvious in view of the prior art described in these patents.
- the compounds exhibit an interesting profile as neuroleptics as evidenced by both biochemical and pharmacological data.
- the biochemical tests revealed an intense action of these compounds on various receptors that are generally considered to be involved in the neuroleptic action ( ⁇ , D 2 5HT 2 receptors, B.L. Largent et al: "Eur. J. Pharmacol.”, 155 , 345-7, 1988; 5HT 1a receptors, B.A. McMillen et al: "Drug Dev.
- the compounds of this invention are characterized by a genuine neuroleptic profile, since advantageously their specificity over 5HT 2 receptors versus D 2 receptors according to D 2 /5HT 2 ratios is higher than that of haloperidol.
- the specificity of the compound of Ex. 1 over ⁇ receptors versus D 2 receptors is also higher than that of haloperidol and surpasses BMY-14802 and risperidone in D 2 /5HT 2 ratio.
- the compound is active on D 3 receptors in the same order as 7-OH-DPAT. All this confers potentially valuable properties on the compounds of this invention as neuroleptics, which are useful in psychosis and schizophrenia, and no extrapyramidal effects are attributed to their interaction with D 2 receptors.
- the neuroleptic activity of the compounds of this invention was confirmed in Animal Pharmacology by oral testing of the inhibition of p -chloro-amphetamine-induced hyperactivity (T.G. Heffner et al: "J.Pharmacol.Exp.Ther.”, 251 , 105, 1989), inhibition of apomorphine-induced hyperactivity (A. Puech et al: “Eur.J.Pharmacol.”, 50 , 291-300, 1978) and inhibition of apomorphine-induced climbing behaviour (P.Protais et al: "Psychopharmacology", 50 , 1-6, 1976).
- mice Male Swiss mice weighing 22-26 g were used. One week prior to experiment, animals were kept in our facilities at a temperature of 20-22°C and 12/12 h light-dark cycle, and had free access to food and water.
- the device consists of a top transparent cage for placing of animals and a lower command panel for starting and calibration of it, as well as a system for animal activity detection.
- mice Male Swiss mice weighing 22-26 g were used. One week prior to experiment, animals were kept in our facilities at a temperature of 20-22°C and 12/12 h light-dark cycle, and had free access to food and water.
- the device consists of a top transparent cage for placing of animals and a lower command panel for starting and calibration of it, as well as a system for animal activity detection.
- mice Male Swiss mice weighing 22-26 g were used. One week prior to experiment, animals were kept in our facilities at a temperature of 20-22°C and 12/12 h light-dark cycle, and had free access to food and water. Two hours prior to experiment, the animals were placed in individual cages without access to food.
- each animal was placed on the bottom of a small upright box (7.5x4.5 cm).
- the walls of the box were made of translucent methacrylate except one of the lateral surfaces (7.5 cm wide) which was a 3-mm wire mesh.
- the compounds of this invention are found to be potentially useful as neuroleptics for treating psychosis and schizophrenia.
- the compound of Example 1 7-[3-(4- p -fluorobenzoyl-1-piperidinyl)propoxy]-chromen-4-one hydrochloride
- the compound of Example 3 7-[3-(4- p -fluorobenzoyl-1-piperidinyl)propoxy]-3-methyl-chromen-4-one hydrochloride
- the compound of Example 4 3-Hydroxymethyl-7-[3-(4- p -fluorobenzoyl-1-piperidinyl)propoxy]chromen-4-one hydrochloride, are preferred.
- the compound of Example 1 was biochemically the most specific over 5HT 2 receptors versus D 2 receptors.
- the compound of Example 3 was very active in animal pharmacological tests and, moreover, its extrapyramidal effects were not very important; the oral administration of this compound to rats at a dose of 50 mg/kg (over 10 times ED 50 - Test C) caused catalepsy in only 60% of treated animals 3 hours after administration and inhibited stereotypy in only 23% of animals.
- the compound of Example 4 was also very active in animal pharmacological tests and did not show very important extrapyramidal effects either; in effect, in rat oral testing, it was necessary to administer a dose of 15 mg/kg of product so that catalepsy could occur in 50% of treated animals.
- IR (KBr): 3200-3600, 2930, 2300-2800, 2680. 1650, 1630, 1595, 1445, 1270, 1230 cm -1 .
- IR (KBr): 3200-3600, 2300-2800, 1680, 1650, 1630, 1595, 1445, 1270, 1230 cm -1 .
- composition for 1 ampoule 7-[3-(4- p -Fluorobenzoyl-1-piperidinyl)propoxy] chromen-4-one hydrochloride 5.0 mg Methyl p -hydroxybenzoate 1.0 mg Propyl p -hydroxybenzoate 0.1 mg Bidistilled water to volume 2.0 ml
- composition for 10 mg tablet 7-[3-(4- p -Fluorobenzoyl-1-piperidinyl)propoxy] chromen-4-one hydrochloride 10.0 mg Corn starch 43.2 mg Talc 6.0 mg Hydrogenated castor oil 2.0 mg Lactose to volume 200.0 mg
- composition for 50 mg tablet 7-[3-(4- p -Fluorobenzoyl-1-piperidinyl)propoxy] chromen-4-one hydrochloride 50.0 mg Corn starch 86.4 mg Talc 12.0 mg Hydrogenated castor oil 4.0 mg Lactose to volume 400.0 mg
Claims (6)
- Verbindungen nach Anspruch 1, nämlich:7-[3-(4-p-Fluorbenzoyl-1-piperidinyl)propoxy]-chromen-4-on;7-[3-(4-p-Fluorbenzoyl-1-piperidinyl)propoxy]-3-methyl-chromen-4-on;3-Hydroxymethyl-7-[3-(4-p-Fluorbenzoyl-1-piperidinyl)propoxy]-chromen-4-onund pharmazeutisch akzeptable Additionssalze davon.
- Chromen-Verbindungen der Formel (I) nach Anspruch 1 oder 2 zur Verwendung bei der Behandlung von Psychose und Schizophrenie.
- Pharmazeutische Zusammensetzung, die wenigstens eine Verbindung der Ansprüche 1 oder 2 gegebenenfalls in Kombination mit pharmazeutisch akzeptablen Trägern und/oder Adjuvantien umfaßt.
- Verwendung einer Verbindung nach Anspruch 1 oder 2 zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung eines von Psychose und Schizophrenie betroffenen Säugers.
- Verfahren zur Herstellung der Chromen-Verbindungen der Ansprüche 1 oder 2, wobei man 4-(p-Fluorbenzoyl)piperidin der Formel II alkyliert mit einem 7-(3-Halopropoxy)chromen-4-on der Formel III worin X Chlor, Brom oder Jod ist, und R1 und R2 wie in Anspruch 1 definiert sind, und gewünschtenfalls eine Verbindung der Formel I in Form der freien Base in ein Säureadditionssalz überführt.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES09400581A ES2101620B1 (es) | 1994-03-18 | 1994-03-18 | Nuevo compuesto derivado del cromeno. |
ES9400581 | 1994-03-18 | ||
ES09401437A ES2101635B1 (es) | 1994-03-18 | 1994-07-01 | Nuevo compuesto derivado del cromeno |
ES9401437 | 1994-07-01 | ||
ES09500163A ES2101644B1 (es) | 1994-03-18 | 1995-01-30 | Nuevo compuesto derivado del cromeno |
ES9500163 | 1995-01-30 | ||
PCT/EP1995/001008 WO1995025733A1 (en) | 1994-03-18 | 1995-03-17 | 4-p-fluorobenzoyl-1-piperidinyl-propoxy-chromen-4-one derivatives, their preparation and their use in the treatment of psychosis and schizophrenia |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0699197A1 EP0699197A1 (de) | 1996-03-06 |
EP0699197B1 true EP0699197B1 (de) | 2000-06-07 |
Family
ID=27240511
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95913143A Expired - Lifetime EP0699197B1 (de) | 1994-03-18 | 1995-03-17 | 4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen-4-on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie |
Country Status (16)
Country | Link |
---|---|
US (1) | US5643927A (de) |
EP (1) | EP0699197B1 (de) |
JP (1) | JP3170287B2 (de) |
AT (1) | ATE193705T1 (de) |
AU (1) | AU683549B2 (de) |
CA (1) | CA2163251A1 (de) |
DE (1) | DE69517371T2 (de) |
DK (1) | DK0699197T3 (de) |
FI (1) | FI955386A0 (de) |
GR (1) | GR3034226T3 (de) |
IL (1) | IL112764A0 (de) |
NO (1) | NO308001B1 (de) |
NZ (1) | NZ282810A (de) |
PH (1) | PH31442A (de) |
PT (1) | PT699197E (de) |
WO (1) | WO1995025733A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117646A (en) * | 1995-04-12 | 2000-06-01 | Ferrer Int | 7-¬3-¬4-(6-fluoro-1,2-benzisoxazole-3-YL)piperidin-1-YL¾propoxy¾3-alkyl-chromen-4-ones their preparation their uses and pharmaceutical compositions comprising them |
ES2144355B1 (es) * | 1997-12-30 | 2001-01-01 | Ferrer Int | Compuestos derivados del cromeno. |
ES2154176B1 (es) * | 1998-09-21 | 2001-10-16 | Ferrer Int | Nuevo procedimiento de obtencion de 3-(hidroximetil)cromen-4-onas. |
WO2002069973A1 (en) * | 2001-03-02 | 2002-09-12 | Sepracor, Inc. | Piperidine-piperazine ligand for neurotransmitter receptors |
US7504395B2 (en) | 2001-07-20 | 2009-03-17 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
JP5380069B2 (ja) * | 2005-03-11 | 2014-01-08 | ハワード フローリー インスティチュート | フラボノイド化合物およびその使用 |
EP1829873A1 (de) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Pyrrazolderivate als Sigma-Rezeptoren-Antagonisten |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
DE3117389A1 (de) * | 1981-05-02 | 1982-11-18 | Boehringer Mannheim Gmbh, 6800 Mannheim | Benzopyranylether, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
US4678787A (en) * | 1985-01-30 | 1987-07-07 | Warner-Lambert Company | 4H-1-benzopyran-4-ones and their sulfur containing analogs |
DK623586A (da) * | 1985-12-27 | 1987-06-28 | Eisai Co Ltd | Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne |
HUT58310A (en) * | 1988-12-21 | 1992-02-28 | Upjohn Co | Anti-atherosclerotic and anti-thrombotic 1-benzopyran-4-one- and 2-amino-1,3-benzoxazin-4-one derivatives, process for producing them and pharmaceutical compositions containing them |
US5278174A (en) * | 1990-06-04 | 1994-01-11 | Scios Nova, Inc. | Sigma binding site agents |
EP0558245A1 (de) * | 1992-02-25 | 1993-09-01 | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY | Heterobicyclische Verbindungen als Alpha-1-Adrenergene und 5HT1A-Rezeptor-Antagonisten |
-
1995
- 1995-02-23 IL IL11276495A patent/IL112764A0/xx not_active IP Right Cessation
- 1995-03-17 CA CA002163251A patent/CA2163251A1/en not_active Abandoned
- 1995-03-17 AT AT95913143T patent/ATE193705T1/de not_active IP Right Cessation
- 1995-03-17 DK DK95913143T patent/DK0699197T3/da active
- 1995-03-17 DE DE69517371T patent/DE69517371T2/de not_active Expired - Fee Related
- 1995-03-17 NZ NZ282810A patent/NZ282810A/en unknown
- 1995-03-17 JP JP52437695A patent/JP3170287B2/ja not_active Expired - Fee Related
- 1995-03-17 EP EP95913143A patent/EP0699197B1/de not_active Expired - Lifetime
- 1995-03-17 WO PCT/EP1995/001008 patent/WO1995025733A1/en active IP Right Grant
- 1995-03-17 US US08/532,791 patent/US5643927A/en not_active Expired - Fee Related
- 1995-03-17 PT PT95913143T patent/PT699197E/pt unknown
- 1995-03-17 AU AU20720/95A patent/AU683549B2/en not_active Ceased
- 1995-03-27 PH PH50033A patent/PH31442A/en unknown
- 1995-11-08 FI FI955386A patent/FI955386A0/fi unknown
- 1995-11-16 NO NO954633A patent/NO308001B1/no not_active IP Right Cessation
-
2000
- 2000-08-17 GR GR20000401911T patent/GR3034226T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL112764A0 (en) | 1995-05-26 |
NO954633L (no) | 1995-11-16 |
AU683549B2 (en) | 1997-11-13 |
WO1995025733A1 (en) | 1995-09-28 |
FI955386A (fi) | 1995-11-08 |
NO954633D0 (no) | 1995-11-16 |
DE69517371T2 (de) | 2001-02-22 |
EP0699197A1 (de) | 1996-03-06 |
JPH08510478A (ja) | 1996-11-05 |
JP3170287B2 (ja) | 2001-05-28 |
FI955386A0 (fi) | 1995-11-08 |
NZ282810A (en) | 1996-11-26 |
NO308001B1 (no) | 2000-07-03 |
PH31442A (en) | 1998-11-03 |
ATE193705T1 (de) | 2000-06-15 |
CA2163251A1 (en) | 1995-09-28 |
PT699197E (pt) | 2000-10-31 |
DK0699197T3 (da) | 2000-08-07 |
US5643927A (en) | 1997-07-01 |
AU2072095A (en) | 1995-10-09 |
GR3034226T3 (en) | 2000-12-29 |
DE69517371D1 (de) | 2000-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1417206B1 (de) | Neue 2h-pyridazin-3-on derivate, pharmazeutische zusammensetzungen davon sowie ein verfahren zur herstellung derselben | |
TW419477B (en) | Diphenylmethylene piperidine derivatives | |
JPH08325257A (ja) | 新規なピペラジン、ピペリジン及び1,2,5,6−テトラヒドロピリジン化合物、これらの製造方法及びこれらを含む医薬組成物 | |
CN102482251B (zh) | 色酮衍生物、其制备方法及其治疗应用 | |
AU2002321669A1 (en) | Novel 2H-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient | |
US5359098A (en) | Intermediates for making sigma binding site agents | |
CN102241667A (zh) | 1-[(4-羟基哌啶-4基)甲基]吡啶-2(1h)-酮衍生物及其制备方法和用途 | |
EP0699197B1 (de) | 4-p-fluorbenzoyl-1-piperidinyl-propoxy-chromen-4-on derivate, deren herstellung und deren verwendung zur behandlung von psychosen und schizophrenie | |
Toja et al. | 1-Alkyl-1, 2, 5, 6-tetrahydropyridine-3-carboxaldehyde-O-alkyl-oximes: A new class of potent orally active muscarinic agonists related to arecoline | |
NO316693B1 (no) | Nye indanolforbindelser, fremgangsmate ved deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
US6187793B1 (en) | 7-[(Piperidin-1-YL)-Propoxy]-chromen-4-one derivatives, their preparation and their pharmaceutical use | |
EP0765323B1 (de) | 4-(6-fluor-1,2-benzisoxazolyl)-1-piperidinyl-propoxy-chromen-4-on-derivate,ihre herstellung und ihre verwendung in der behandlung von psychosen, schizophrenie und angstzuständen | |
KR0182088B1 (ko) | 4-p-플로오로벤조일-1-피페리디닐-프로폭시-크로멘-4-온 유도체, 그의 제조, 및 그의 정신병 및 정신분열증 치료에의 이용 | |
JP3478405B2 (ja) | 新規ベンジル及びベンズヒドリルアルコール類 | |
IE49998B1 (en) | 4-(naphthalenyloxy)piperidine derivatives | |
US6448268B1 (en) | Aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone derivatives as 5-ht1 receptor antagonists | |
JPH037229A (ja) | 脳神経機能改善剤 | |
JPH09268188A (ja) | イミダゾール−2−オン誘導体およびその塩 | |
US5512566A (en) | Tricyclic compounds having affinity for the 5-HT1A receptor | |
US5798361A (en) | 5H-thiazolo 3,2-a!pyrimidin-5-one derivatives | |
CZ346999A3 (cs) | 7-[(piperidin-l-yl)-propoxy]chromen-4-onové deriváty | |
MXPA99007944A (en) | 7-[(piperidin-1-yl)-propoxy]-chromen-4-one derivatives, their preparation and their pharmaceutical use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19951024 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19980730 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 20000607 |
|
REF | Corresponds to: |
Ref document number: 193705 Country of ref document: AT Date of ref document: 20000615 Kind code of ref document: T |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: ORTIZ, JOSE, A. Inventor name: SACRISTAN, AURELIO Inventor name: BOLOS, JORDI Inventor name: FOGUET, RAFAEL |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69517371 Country of ref document: DE Date of ref document: 20000713 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
ITF | It: translation for a ep patent filed |
Owner name: STUDIO TORTA S.R.L. |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20000727 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IE Payment date: 20010115 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20010119 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DK Payment date: 20010302 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20010305 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LU Payment date: 20010313 Year of fee payment: 7 Ref country code: GB Payment date: 20010313 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20010323 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20010327 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: AT Payment date: 20010328 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20010402 Year of fee payment: 7 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20010531 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GR Payment date: 20010806 Year of fee payment: 7 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20010919 Year of fee payment: 8 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020317 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020317 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020317 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020318 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020318 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020331 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020331 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20020402 |
|
BERE | Be: lapsed |
Owner name: S.A. *FERRER INTERNACIONAL Effective date: 20020331 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20021001 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20021001 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20021007 |
|
EUG | Se: european patent has lapsed |
Ref document number: 95913143.4 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20020317 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20021129 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20021001 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20030930 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20030930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED. Effective date: 20050317 |